Nab-paclitaxel ( Abraxane) is nanoparticle albumin–bound paclitaxel.
Studies have shown that elderly patients have an increased risk of severe myelosuppression, severe neuropathy and a higher incidence of cardiovascular events.
- TRADE NAMES: Abraxane; Paclimer; Paxene; Taxol (Bristol-Myers Squibb)
- INDICATIONS: Breast cancer and metastatic carcinoma of the ovary
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Taxane
- HALF-LIFE: 5–17 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Bexarotene, Buspirone, Carbamazepine, Cisplatin, Clarithromycin, Delavirdine, Doxorubicin, Efavirenz, Eletriptan, Felodipine, Gadobenate, Gemfibrozil, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Lovastatin, Nefazodone, Nelfinavir, Repaglinide, Rifampin, Ritonavir, Rosiglitazone, Saquinavir, Sildenafil, Simvastatin, Telithromycin, Teriflunomide, Thalidomide, Trastuzumab, Triazolam
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of albumin-bound paclitaxel in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/18/2025
